Evaluation of heart failure pathophysiology targeting cardiac cyclic GMP

Evaluation of heart failure pathophysiology targeting cardiac cyclic GMP - Investigation for cardiac derived cyclic GMP in patients with heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049990

Enrollment

Registered

2023-01-12

Start date

2022-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients with heart failure who will undergo right heart catetherizaion 2) patients with heart failure (Stage C and D)

Exclusion criteria

Exclusion criteria: 1) Patients who are receiving intravenous administration of carperitide or nitrate, or those who received them within 24 hours from the gaining the consent. 2) Patients who are receiving dialysis

Design outcomes

Primary

Measure	Time frame
Heart failure treatment responsiveness as changes of plasma BNP levels	—

Countries

Japan

Contacts

Public ContactHiroyuki Takahama

Tohoku university hospital Department of cardiovascular medicine

takahama@cardio.med.tohoku.ac.jp022-717-7153

Outcome results